Effects of Anti-inflammatory Medication on Indoleamine 2,3 Dioxygenase Activity

Shazia Dawood a#, Samina Bano b≡, Sadia Sundus c®, Asma Aijaz d#, Talat Samreen d# and Mohsin Ali Usmani e†

a Department of Pharmacy And Allied Health Sciences, Iqra University, 03319764733, Pakistan.
b Department of Biochemistry, Karach University, Pakistan.
c Anatomy Department, Iqra University, 03002850489, Pakistan.
d Anatomy Department, Karachi Medical and Dental College, Pakistan.
e Medicine Department, Karachi Medical and Dental College, Pakistan.

Authors’ contributions
This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

ABSTRACT

Objective: To study the effects of anti-inflammatory medication on Indoleamine 2,3 dioxygenase activity.
Research Design: This was an investigational study.
Methodology: Eighteen fully grown albino rats separated into control and two treated sets. Both treated sets were given indomethacin (50mg/1000g) orally. For acute treatment first treated set was sacrificed after 3.5 hrs & for chronic treatment second set was sacrificed after 3 days. However, control set animals were given an equivalent amount of vehicle.
Results: Outcomes shows that serum Indoleamine 2,3 dioxygenase (IDO) enzyme activity was suppressed after acute treatment while serum IDO activity were increased after chronic treatment however no significant effect was seen on brain IDO.
Conclusion: It is concluded that indomethacin has not shown any significant effect on brain IDO. But inhibits serum IDO activity.
Keywords: Tryptophan (TRP); kynurenine (KYN); Indoleamine 2,3 dioxygenase (IDO); Mesenchymal stromal cells (MSCs); tryptophan-2,3-dioxygenase (TDO).

1. INTRODUCTION

Tryptophan is a precursor of serotonin & kynurenine pathway metabolites, in which metabolization takes place in kidney cells, liver cells and CNS. Tryptophan 2,3-dioxygenase and indolamine 2,3-dioxygenase metabolized 95% Tryptophan [1,2]. Kynurenine pathway is triggered by social stress, depression and inflammatory elements [3]. At present, numerous factors produced by Mesenchymal stromal cells (MSCs) or as a reaction with target immune cells like indoleamine2,3-dioxygenase (IDO), PGE2, interleukin10, proinflammatory cytokines secreted by T-cells stimulates IDO & PGE2. Metabolism of TRP activated by pro inflammatory cytokines are the main cause of depression [4]. Depression appears as a result of ailment in response to severe inflammation due to kynurenine metabolism pathway which produce neurotoxic metabolites such as quinolinic acid [5,6]. Tryptophan metabolites are triggered due to inflammation and they have immunosuppressive properties [7]. Inflammation reduces the serotonin accessibility & raises kynurenine synthesis [8]. Tryptophan with the help of tryptophan 2,3-dioxygenase (TDO) mediates tumor related immunosuppression, which was stimulated by PGE2 [9]. Elevated Kynurenic acid causes psychosis, mental impairments like schizophrenia and bipolar disorders [10]. Kynurenine pathway plays a key role in producing nicotinamide adenine dinucleotide, which means that it regulates immune response & essential constituent of behavioral changes in depression and schizophrenic patients. Kynurenine metabolism is altered by workout, electroconvulsive treatment & NSAIDs [11].

NSAIDs modulates IFN- alpha-induced neurochemical variations thus prevents depression. Indomethacin an important NSAIDs therapeutically used as analgesic, anti-inflammatory and antipyretic agent [12]. Indoleamine 2,3-dioxygenase-1 (IDO-1) speed up the L-tryptophan metabolism, which produces numerous immunosuppressive metabolites, like kynurenine. Thus it causes immunosuppression, T cell negative regulation & contribute in tumor management [13]. Indoleamine 2,3-dioxygenase (IDO), enhances nitric oxide synthase liable for breakdown of tryptophan and arginine [14]. IDO act as main immunoregulator & transforms tryptophan into kynurenine, which causes cytotoxicity and apoptosis in tumor histology [15,16].

IDO1 activity is low in normal tissues while raised in cancers due to induction by interferons [17,18].

Indomethacin cox-2 inhibitor exhibited raised IDO1 inhibitory activity, which is beneficial for the malignant cells immunotherapy by suppressing interleukin-10 & prostaglandin E2 [19,20]. In this investigational study we want to evaluate the effects of indomethacin on IDO activities.

2. MATERIALS AND METHODS

This study took place in biochemistry department & endorsement was taken from ethical committee of KU [18]. Wistar rats of 150-250 gm weight were used in this investigational study & were kept in coops at room temperature, one week earlier the start of experiment. Rats were separated into three groups, six rats per group. Control group get 3 ml (ethanol: saline 1:2 ratio) orally, treated groups get Indomethacin (Adamjee Pharmaceutical) (50mg/1000gm/3ml) orally & sacrificed after 3.5 hr and 3 days correspondingly. Frozen sections of brain were weighed and homogenized in 12% 2ml HClO & 1ml ice-cold water solution per gm of brain tissue for 1 min, them left in ice-cold tubes for 10 min. Then centrifuge for 10 min at 4°C, then 0.5 ml portion of filtrate were used to find out IDO enzyme activity by evaluating ratio of KYN/TRP in blood serum and CNS [21]. L-tryptophan and Kynurenine were purchased from Sigma chemicals.

For data analysis one-way ANOVA followed by Tukey’s test used. Variance between the two groups were considered significant when \( P<0.05 \).

3. RESULTS

3.1 Acute and Chronic Influence of Indomethacin on Blood Serum Indoleamine 2,3-Dioxygenase Activity

Statistical analysis indicates substantial influence of indomethacin on blood serum Tryptophan \( (F=12.8, P<0.01) \), Kynurenine \( (F= 112.2, P<0.001) \) & TRP/KYN ratio \( (F=25, P<0.001) \) correspondingly. Tukey’s test showed
Table 1. Acute & chronic influence of indomethacin on blood serum Indoleamine 2,3-dioxygenase activity

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Control</th>
<th>Acute</th>
<th>Chronic</th>
<th>Anova (one way)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood serum (total TRP µg/ml)</td>
<td>14.7±1.5</td>
<td>9.2±0.06*</td>
<td>7.9±.39*</td>
<td>F=12.8 (P&lt;0.01)</td>
</tr>
<tr>
<td>Blood serum (Kynurenine ng/ml)</td>
<td>620±4.4</td>
<td>299±31*</td>
<td>646±3.8</td>
<td>F=112.2 (P&lt;0.001)</td>
</tr>
<tr>
<td>KYN/TRP</td>
<td>49.9±5.0</td>
<td>37±2.8*</td>
<td>69.9±0.07*</td>
<td>F=25 (P&lt;0.001)</td>
</tr>
</tbody>
</table>

Values: Mean±SEM
*P<0.01
One way ANOVA was used for statistical analysis.

Table 2. Acute and chronic influence of indomethacin (50mg/kg) on CNS indoleamine 2,3-dioxygenase activity

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Control</th>
<th>Acute</th>
<th>Chronic</th>
<th>Anova (One way)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CNS TRP µg/g</td>
<td>3.2±0.05</td>
<td>5.5±0.03*</td>
<td>5.8±0.1*</td>
<td>F=131.1</td>
</tr>
<tr>
<td>CNS Kynurenine ng/g</td>
<td>80±4.9</td>
<td>127±13.5*</td>
<td>168±27.2*</td>
<td>F=27.2</td>
</tr>
<tr>
<td>KYN/TRP</td>
<td>24.6</td>
<td>23.0</td>
<td>30.4</td>
<td>F=4.9</td>
</tr>
</tbody>
</table>

Values: Mean±SEM.
*P<0.01
One way ANOVA was used for statistical analysis.

considerable reduction in blood serum total Tryptophan in acute (37%, P<0.01) & chronic (46%, P<0.01) cases correspondingly in comparison to control. Outcomes revealed a considerable reduction in blood serum Kynurenine in acute case (51.6%, P<0.001) however insignificant effect on blood serum Kynurenine is observed in chronic case in comparison to control. Considerably reduced blood serum KYN/TRP ratio (25.8%, P<0.01) observed in acute cases however ratio was raised in chronic case (40%, P<0.001) in comparison to control. (Table 1)

3.2 Acute and Chronic Influence of Indomethacin on CNS Indoleamine 2,3-Dioxygenase Activity

Statistical analysis indicates substantial influence of indomethacin on CNS Tryptophan (F=131.1, P<0.01), Kynurenine (F=27.2, P<0.01) & KYN/TRP ratio (F=4.9, P<0.01). Tukey’s test showed considerably raised CNS Tryptophan in acute case (71%, P<0.01) & (81%, P<0.01) in chronic cases in comparison to control. Considerably raised CNS Kynurenine in acute case (58%, P<0.01) and (110%, P<0.01) in chronic case in comparison to control. (Table 2).

4. DISCUSSION

IDO controls the L-Tryptophan levels, and neurotoxic metabolites. Its hyperactivity raised level of kynurenine pathway metabolites especially 3-hydroxykynurenine and quinolinic acid. Enzyme activity can be calculated by (KYN/TRP) proportion. IDO act as main immunoregulator & transforms tryptophan into kynurenine, which causes cytotoxicity and apoptosis in tumor histology [15,16]. Indomethacin cox-2 inhibitor exhibited raised IDO1 inhibitory activity, which is beneficial for the malignant cells immunotherapy by suppressing interleukin-10 & prostaglandin E2 [19,20].

Our results showed that acute treatment of Indomethacin inhibits serum IDO but chronic treatment shows induction of IDO. Our outcomes showed the induction of Indoleamine 2,3 dioxygenase by releasing pro-inflammatory cytokines. It had insignificant impact on CNS Indoleamine 2,3 dioxygenase activity but CNS Tryptophan & kynurenine levels become raised
after the indomethacin therapy. Similar results are observed by [19,20] who said that it inhibits IDO activity. Previously it was reported that Diclofenac Sodium prevents hepatic tryptophan-2,3-dioxygenase enzyme activity in chronic therapy, whereas augments CNS Indoleamine 2,3 dioxygenase activity following both acute and chronic Diclofenac Sodium therapy, resulting in raised cerebral kynurenine acid and/or quinolinic acid concentrations [22]. Furthermore similar results are also observed by [23] that indomethacin therapy (50mg/kg, intra peritoneally, 3.5hr) raised the concentration of CNS kynurenine acid participates in Schizophrenia.

5. CONCLUSION

It is concluded that indomethacin has insignificant impact on CNS Indoleamine 2,3 dioxygenase activity but inhibits serum IDO activity.

DISCLAIMER

The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

CONSENT

It is not applicable.

ETHICAL APPROVAL

As per international standard or university standard written ethical approval has been collected and preserved by the author(s).

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES


